Alembic Pharmaceuticals Limited · NSE:APLLTD
Alembic Pharmaceuticals — Q3 FY2017 Earnings Presentation
8 slides from Alembic Pharmaceuticals's earnings presentation, Jan 25, 2017
Slide 1: Alembic Pharmaceuticals Ltd Investor Presentation
Alembic Pharmaceuticals Ltd Investor Presentation January-2017 Contents 1. Milestones 2. Quarterly Highlights 3. Nine month Highlights 4. Business - International - India Branded 5. Strategy 6. Financials - Annual - Latest Quarter 1/25/2017
Slide 2: Safe Harbor Statement / Milestones
Safe Harbor Statement Materials and information provided during this presentation may contain ‘forward-looking statements’. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to diffe
Slide 3: Highlights - Q3 FY17 and YTD Dec FY17
Highlights - Q3 FY 17 Financial Highlights > Net Sales at Rs 7762 mn > EBITDA margins at 19% at Rs 1454 mn > Net Profit at Rs 861 mn > R&D spend is Rs 1167 mn for the quarter which is 15% of net sales. This is up by 66 % (YoY) India Branded Formulations (Rs. 2941 mn) > Business grew by 2% > Specialt
Slide 4: International Business
India * International . Generics Ex-india API ‘Business — Secs = = <== — Sales CAGR% Rs 156 21% Manufacturing: 9% Formulation: Baddi and Sikkim for India market FDA approved Oral Solids in Vadodara 12% Oncology (OSD, Injectables), General Injectables, Derma. API: 3 FDA approved facilities in Vadodar
Slide 5: India Branded
India Branded Sales (Rs bn) Marketing Organisation > 5000 + marketing team ‘Added 1000 over last two years > 17 marketing divisions Added new divisions in gynaecology, cardiology , Gl, urology > 170 products Launch 20-25 products every year % of Domestic Formulations Key Achievements > Leadership in
Slide 6: Strategy
‘Strategy Competitive position Growth drivers CAGR 21% i us: Reply expand breadth and quality of pipeline ce an OSD grid, half of grid is external — injectable, ad ‘and ophtahalmics $ Peooute to gain time and leverage financial resource ‘Build manufacturing capacties repidly, use CMOs , de-risk Ex-U
Slide 7: Quarterly Financials: EBITDA and Business Sales
Sales (Rs bn) EBITDA (Rs bn) 38 15 Q3FY16 Q3FY17 Business Sales Q3FY16 Q3FY17 Sales (Rs bn) EBITDA (Rs bn) 86 48 YTO DEC FY16 YTD DEC FY17 '® International n india TAP 16% 19% YTD DEC FY16 YTD DEC FY17 YTD DEC FY16 YTD DEC FY17 1/25/2017
Slide 8: Latest Shareholding Pattern
‘Latest Shareholding Pattern % of Total Shareholding = Promoter & Promoter group = FUFIUMEF = Public Market capitalization INR 112 bn Total paid-up share capital 377.03mn Total number of shares O/S_ | 188.52mn No. of shareholders >50K Free float market INR 29 bn capitalization THANK YOU 1/25/2017
Alembic Pharmaceuticals — Q3 FY2017 Earnings Presentation on 6ix